Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Braz J Med Biol Res ; 49(6)2016 May 24.
Artículo en Inglés | MEDLINE | ID: mdl-27240293

RESUMEN

New generation antidepressant therapies, including serotonin-norepinephrine reuptake inhibitor (SNRIs), were introduced in the late 1980s; however, few comprehensive studies have compared the benefits and risks of various contemporary treatments for major depressive disorder (MDD) in young patients. A comprehensive literature search of PubMed, Cochrane, Embase, Web of Science, and PsycINFO databases was conducted from 1970 to January 2015. Only clinical trials that randomly assigned one SNRI or placebo to patients aged 7 to 18 years who met the diagnostic criteria for major depressive disorder were included. Treatment success, dropout rate, and suicidal ideation/attempt outcomes were measured. Primary efficacy was determined by pooling the risk ratios (RRs) of treatment response and remission. Acceptability was determined by pooling the RRs of dropouts for all reasons and for adverse effects as well as suicide-risk outcomes. Five trials with a total of 973 patients were included. SNRIs were not significantly more effective than placebo for treatment response but were for remission. The comparison of patients taking SNRIs that dropped out for all reasons and those taking placebo did not reach statistical significance. Significantly more patients taking SNRIs dropped out for adverse effects than those taking placebo. No significant difference was found in suicide-related risk outcomes. SNRI therapy does not display a superior efficacy and is not better tolerated compared to placebo in these young patients. However, duloxetine has a potential beneficial effect for depression in young populations, showing a need for further research.


Asunto(s)
Antidepresivos/uso terapéutico , Trastorno Depresivo Mayor/tratamiento farmacológico , Ensayos Clínicos Controlados Aleatorios como Asunto , Inhibidores de Captación de Serotonina y Norepinefrina/uso terapéutico , Adolescente , Niño , Ciclopropanos/uso terapéutico , Succinato de Desvenlafaxina/uso terapéutico , Clorhidrato de Duloxetina/uso terapéutico , Femenino , Humanos , Masculino , Milnaciprán , Placebos/uso terapéutico , Resultado del Tratamiento , Clorhidrato de Venlafaxina/uso terapéutico
2.
Rev. bras. pesqui. méd. biol ; Braz. j. med. biol. res;49(6): e4806, 2016. tab, graf
Artículo en Inglés | LILACS | ID: biblio-951682

RESUMEN

New generation antidepressant therapies, including serotonin-norepinephrine reuptake inhibitor (SNRIs), were introduced in the late 1980s; however, few comprehensive studies have compared the benefits and risks of various contemporary treatments for major depressive disorder (MDD) in young patients. A comprehensive literature search of PubMed, Cochrane, Embase, Web of Science, and PsycINFO databases was conducted from 1970 to January 2015. Only clinical trials that randomly assigned one SNRI or placebo to patients aged 7 to 18 years who met the diagnostic criteria for major depressive disorder were included. Treatment success, dropout rate, and suicidal ideation/attempt outcomes were measured. Primary efficacy was determined by pooling the risk ratios (RRs) of treatment response and remission. Acceptability was determined by pooling the RRs of dropouts for all reasons and for adverse effects as well as suicide-risk outcomes. Five trials with a total of 973 patients were included. SNRIs were not significantly more effective than placebo for treatment response but were for remission. The comparison of patients taking SNRIs that dropped out for all reasons and those taking placebo did not reach statistical significance. Significantly more patients taking SNRIs dropped out for adverse effects than those taking placebo. No significant difference was found in suicide-related risk outcomes. SNRI therapy does not display a superior efficacy and is not better tolerated compared to placebo in these young patients. However, duloxetine has a potential beneficial effect for depression in young populations, showing a need for further research.


Asunto(s)
Humanos , Masculino , Femenino , Niño , Adolescente , Ensayos Clínicos Controlados Aleatorios como Asunto , Trastorno Depresivo Mayor/tratamiento farmacológico , Inhibidores de Captación de Serotonina y Norepinefrina/uso terapéutico , Antidepresivos/uso terapéutico , Placebos/uso terapéutico , Ciclopropanos/uso terapéutico , Succinato de Desvenlafaxina/uso terapéutico , Clorhidrato de Duloxetina/uso terapéutico , Milnaciprán
3.
Int Clin Psychopharmacol ; 22(3): 153-8, 2007 May.
Artículo en Inglés | MEDLINE | ID: mdl-17414741

RESUMEN

The aim of this study is to evaluate the efficacy of milnacipran in the acute treatment of patients with panic disorder. Thirty-one patients who met Diagnostic and statistical manual of mental disorders-IV criteria for panic disorder with or without agoraphobia were included in the study. Patients were initially treated with milnacipran 25 mg twice daily and then 50 mg twice daily until the 10th week. The treatment outcome and panic disorder severity were determined by the Panic Disorder Severity Scale, Panic Inventory, Clinical Global Impression and Hamilton Anxiety Scale, all of which were applied during every evaluation interview. Quality of life (WHOQOL-bref) was evaluated at baseline and at the end of the study. Missing data were handled by using the last observation carried forward for all participants who had taken at least one dose of study medication. Intention-to-treat was used in the analyses. Pharmacological treatment resulted in a clinically and statistically significant mean reduction in all severity measures. Remission (Clinical Global Impression < or = 2) was obtained in 58.1% of the sample. Regarding WHOQOL, we found a significant improvement (P<0.05) across treatment in all the domains studied. Although results may be influenced by the open design of this pilot study and by the small sample size, our findings suggest that milnacipran may be effective for the treatment of panic disorder and justify further research.


Asunto(s)
Agorafobia/tratamiento farmacológico , Ciclopropanos/administración & dosificación , Trastorno de Pánico/tratamiento farmacológico , Inhibidores Selectivos de la Recaptación de Serotonina/administración & dosificación , Adulto , Agorafobia/diagnóstico , Agorafobia/psicología , Ciclopropanos/efectos adversos , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Milnaciprán , Trastorno de Pánico/diagnóstico , Trastorno de Pánico/psicología , Inhibidores Selectivos de la Recaptación de Serotonina/efectos adversos , Resultado del Tratamiento
4.
Neurochem Res ; 31(4): 571-7, 2006 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16758367

RESUMEN

Serotonin (5-HT) and noradrenaline (NA) are involved in both pathogenesis and recovery from depression and anxiety. We examined the effects of acute and chronic treatment with milnacipran, a serotonin/noradrenaline reuptake inhibitors (SNRIs) antidepressant, on anxiety and memory retention in rats. Male Wistar rats received acute or chronic administration of milnacipran (12.5, 25 or 50 mg/kg) or saline (control group). The animals were separately submitted to elevated plus-maze, inhibitory avoidance and open-field tasks 1 h after injection, in the acute group, or 23 h after last injection, in the chronic group. Our results showed an anxiolytic-like effect after chronic administration of milnacipran at doses of 25 and 50 mg/kg. The treatment does not interfere in memory retention and habituation to a novel environment at any doses studied. These findings support that milnacipran, an established SNRIs antidepressant, can also be useful in the treatment of anxiety disorders.


Asunto(s)
Ansiolíticos , Ansiedad/tratamiento farmacológico , Ciclopropanos , Memoria/efectos de los fármacos , Inhibidores Selectivos de la Recaptación de Serotonina , Animales , Ansiolíticos/farmacología , Ansiolíticos/uso terapéutico , Conducta Animal/efectos de los fármacos , Ciclopropanos/farmacología , Ciclopropanos/uso terapéutico , Aprendizaje/efectos de los fármacos , Masculino , Milnaciprán , Actividad Motora/efectos de los fármacos , Ratas , Ratas Wistar , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico
5.
Physiol Behav ; 88(1-2): 82-7, 2006 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-16624346

RESUMEN

We previously demonstrated that repeated swim stress produces long-term cutaneous hyperalgesia in rats. We have now determined the effect of stress upon muscle nociception and the anti-nociceptive efficacy of the norepinephrine-serotonin reuptake inhibitor, milnacipran (MIL) in this model. Rats were subjected to either 10-20 min daily sessions of forced swimming (FS) for 3 days, or sham swimming (SS) or control (CT). Maximal forelimb grip strength and hot plate response latencies were estimated before and after the conditioning to assess muscle and thermal nociception, respectively. MIL (1-30 mg/kg/i.p.) or vehicle was started 7 days before the conditioning protocol. There were significant reductions in maximal grip strength and hot plate latencies only in FS/vehicle rats. Subsequent carrageenan administration (2 mg/75 microl each triceps) diminished grip strength in all groups 24 h later, with grip strength lower in FS/vehicle and SS/vehicle rats than in CT/vehicle rats. Treatment with MIL before the stress prevented the reduction in grip strength in all groups but it was ineffective in preventing FS-induced reductions in hot plate response latencies. Thus, repeated stress produces muscle hyperalgesia that can be pharmacologically dissociated from cutaneous hyperalgesia, suggesting that different mechanisms may underlie these two phenomena.


Asunto(s)
Antidepresivos/uso terapéutico , Ciclopropanos/uso terapéutico , Hiperalgesia/tratamiento farmacológico , Hiperalgesia/fisiopatología , Estrés Psicológico/fisiopatología , Análisis de Varianza , Animales , Relación Dosis-Respuesta a Droga , Masculino , Milnaciprán , Músculos/inervación , Dimensión del Dolor/métodos , Ratas , Ratas Sprague-Dawley , Tiempo de Reacción/efectos de los fármacos , Piel/inervación , Estrés Psicológico/complicaciones , Natación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA